Salvage High-Dose-Rate Interventional Radiotherapy (Brachytherapy) Combined with Surgery for Regionally Relapsed Head and Neck Cancers.
Tamer SororJustina PaulCorinna MelchertChristian IdelDirk RadesKarl-Ludwig BruchhageGyörgy KovacsAnke LeichtlePublished in: Cancers (2023)
(1) Background: to report on the use of high-dose-rate (HDR) interventional radiotherapy (brachytherapy, IRT) as a salvage treatment for patients with regionally relapsed head and neck cancers. (2) Methods: A retrospective study of 60 patients treated with HDR-IRT for loco-regionally relapsed head and neck cancers at our institution (2016-2020). Treatment procedure, results, and related toxicities were collected. Local and overall survival outcomes were analyzed. (3) Results: The median follow-up was 22.4 months. Twenty-nine (48.3%) patients had locoregional recurrences with a median time of 28.9 months. The local-recurrence free-survival was 88.1% and 37.3% at 3 years and 5 years. At the last follow-up, 21 patients were alive and the median time to death was 24 months. The overall survival was 39.2% and 16.6% at 3 years and 5 years. Collectively, there were 28 events of grade ≥ 3 late toxicities recorded in 21 patients (35%). (4) Conclusions: Salvage HDR-IRT combined with surgery offers a second-line curative treatment option for regionally relapsed head and neck cancers with acceptable outcomes and toxicities.
Keyphrases
- high dose
- end stage renal disease
- acute myeloid leukemia
- acute lymphoblastic leukemia
- newly diagnosed
- chronic kidney disease
- ejection fraction
- radiation therapy
- prognostic factors
- multiple myeloma
- peritoneal dialysis
- low dose
- minimally invasive
- early stage
- diffuse large b cell lymphoma
- stem cell transplantation
- type diabetes
- radiation induced
- coronary artery bypass
- acute coronary syndrome
- patient reported outcomes
- coronary artery disease
- atrial fibrillation
- drug induced